Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pucotenlimab + Cetuximab + Albumin-bound Paclitaxel Sequential Radiotherapy for Locally Advanced Hypopharyngeal Cancer
ChiCTR2500107566Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pucotenlimab in hypopharyngeal cancer, sponsored by The First Hospital of Jilin University. Primary endpoint: Objective Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
hypopharyngeal cancer
Beyond the preview
Go deeper on ChiCTR2500107566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107566.